Quality-Of-Life Data Favor Stenting Over Drugs Only In Short-Term
This article was originally published in The Gray Sheet
Executive Summary
A newly published quality-of-life analysis from the high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease
You may also be interested in...
Follow-up Analyses Rekindle Debate On The Impact Of COURAGE
Cardiologists are not finished picking apart the controversial COURAGE study. Nine new sub-analyses of the highly-publicized trial were presented last week at the American Heart Association's Scientific Sessions in Orlando
Physicians Predict COURAGE Will Reduce U.S. Stent Procedures About 5%
The highly publicized COURAGE trial will cause a roughly 5% reduction in the number of stent procedures in the United States, according to Dartmouth Medical School's Aaron Kaplan, M.D., and Carl Szot, M.D
COURAGE Suggests Stents Do Not Benefit Stable Coronary Disease Patients
Results of the highly anticipated COURAGE trial challenge the widespread assumption that stents improve outcomes in patients with stable coronary disease, but several observers believe the findings' impact on the stent market will be modest